Abbott Laboratories

Abbott Laboratories

ABTNYSEHealthcare
$104.88
up +0.2 (+0.19%)

1-Year Price

-21.41% past year
Abbott Laboratories (ABT) 1-year price chart: down 21.41% from $133.47 on Oct 2025 to $104.89 on Oct 2026. Closing range $82.56 to $134.59.

EquityGlimpse Score

Overall
5.9/10
Wide Moat

Strong, durable competitive advantages versus peers.

Growth
2

Valuation, profitability, financial health, dividend and sentiment scores for Abbott Laboratories (ABT) are available to EquityGlimpse members.

Market Cap
181.48B
P/E Ratio
33.50
EPS
$3.73
52W High
$132.03
52W Low
$81.97
Volume
7.95M
Beta
0.58
Dividend Yield
1.88%
Fair value estimate: sign up to see
Is ABT over- or undervalued? Run DCF and multiples models on EquityGlimpse.
See fair value

Key Financial Metrics

Price to Sales
4.94
Price to Book
4.20
EV/EBITDA
18.91
Free CF per Share
$4.23
Op. CF per Share
$5.48
Debt to Equity
0.29
Gross Margin
55.51%
Net Margin
14.72%

About Abbott Laboratories

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

CEO
Robert Ford
Industry
Medical - Devices
Employees
115,000
IPO Date
1980-03-17
Country
US
Website
Unlock Full Analysis

Get the complete picture on Abbott Laboratories

Sign up for EquityGlimpse to access deep fundamental data, AI reports, valuation models, and real-time tracking for ABT and 8,500+ other stocks.

30 Years of Financials
Income statements, balance sheets, and cash flows with 70+ interactive charts
AI-Powered Analysis
Generate professional research reports with 15+ AI models
DCF Valuation
Run discounted cash flow models with customizable assumptions
Portfolio Tracking
Track real-time P&L, sector allocation, and dividend projections
Earnings Intelligence
Surprise tracking, revision momentum, and whisper estimates
Insider & Congress Trades
Monitor what insiders and Congress members are buying and selling

Starting at $8.25/month. 7-day free trial. Cancel anytime.